Figure 1
F. nucleatum statuses of CRC patients and controls. (A) Patients with CRC were categorized according to tumor stage (I/II: early stage, III/IV: late stage). F. nucleatum prevalence was significantly higher in CRC patients at early and late stages than in controls (92% and 76.9% vs. 0%, respectively; Fisher’s exact test, P < 0.0001, each). (B) Tissues of CRC patients were collected from carcinoma tissues (CTs), adjacent normal tissues (ATs) and/or normal tissues (NTs) from non-CRC sites. F. nucleatum was significantly higher in CTs (82.1%) than in ATs (38.9%) and NTs (33.3%) of CRC patients (CT vs. AT, CT vs. NT, AT vs. T, and NT vs. T; Fisher’s exact test, P = 0.0002, < 0.0001, 0.0008, and 0.003, respectively) and was significantly higher in CTs than in tissues (Ts) of controls (P < 0.0001). (C) Comparison of the prevalence of the fadA gene revealed significant differences between the CTs of patients and tissues (Ts) of controls (69.2% vs. 9.5%; Fisher’s exact test, P < 0.0001). Four asterisks (****) indicate P < 0.0001, three asterisks (***) indicate P < 0.001, and two asterisks (**) indicate P < 0.001; Fisher’s exact test was performed using GraphPad Prism version 5.0 for Windows.
